CRISPR Therapeutics CRSP Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's net income?
- CRISPR Therapeutics (CRSP) reported net income of -$122.93M in Q1 2026.
- How has CRISPR Therapeutics's net income changed year-over-year?
- CRISPR Therapeutics's net income increased by 9.6% year-over-year, from -$136M to -$122.93M.
- What is the long-term trend for CRISPR Therapeutics's net income?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's net income has grown at a -5.4% compound annual growth rate (CAGR), from -$650.18M to -$581.6M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.